The latest research confirms that three doses of the vaccine will still confirm the diagnosis of the new coronary pneumonia (COVID-19) Omicron variant virus, but it can still prevent severe disease and death. U.S. vaccine stocks have had a bleak past week.
MarketWatch and Zero Hedge reported on the 20th that the latest research published in The Lancet, an authoritative peer-reviewed medical journal, showed that the third dose of mRNA vaccine could not prevent the human body from being infected with the Omicron variant virus, but confirmed cases All had only mild or moderate symptoms, proving that vaccines can indeed prevent severe illness and death.
According to the study, seven Germans who visited Cape Town, South Africa, between late November and early December 2021 were the first recorded cases of breakthrough Omicron infection after three doses. The Germans received at least two doses of an mRNA vaccine developed by Pfizer’s BioNTech SE (BNT) or Moderna, the study showed.
The Germans were between the ages of 25 and 39 and had no history of obesity or other related medical conditions, the report said. All tested negative before arriving in Cape Town and had never been infected before. Five received three doses of Pfizer’s BNT vaccine, one received one dose of Moderna followed by the next two doses of Pfizer, and one received AstraZeneca (AZ) vaccine first, followed by both doses of Pfizer.
All developed respiratory symptoms from Nov. 30 to Dec. 2 and eventually became mild to moderate patients.
According to the report, the study showed that “three doses of the COVID-19 mRNA vaccine are still not enough to prevent healthy normal people from becoming symptomatic infected patients.” Not only that, the study confirmed that “vaccine needs to be upgraded to provide greater protection against symptomatic infection”.
U.S.-listed vaccine stocks have struggled recently. So far this week, BioNTech, Modena, and Novavax have fallen 20.14%, 18.18%, and 18.46%, respectively.